News

Filter

Current filters:

EuropeLucentis

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

15-09-2014

Health policies which favor using ranibizumab for treating eye disease in older people over safety concerns…

AvastinbevacizumabBiotechnologyEuropeLucentisNovartisOphthalmicsPricingRanibizumab InjectionRoche

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

16-06-2014

Steven Bradshaw, a UK-based drug policy expert and former ophthalmologist, is disappointed at the news…

AvastinEuropeItalyLucentisOphthalmicsPharmaceuticalRegulationRoche

Novartis presents real world data for Lucentis

Novartis presents real world data for Lucentis

09-05-2014

Swiss drug major Novartis has reported data on the eye drug Lucentis (ranibizumab) at the 2014 Association…

AMDEuropeHealthLucentisMajorMedicineNovartisOphthalmicsOphthalmologyPharmaceuticalResearch

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Back to top